Accès ouvert déclaré 2023 article

Quality of life and response shift effect of diffuse large B‐cell lymphoma French patients included in prospective real‐life REALYSA cohort in the first year after diagnosis

Amélie Anota, Marco Basset, A. Belot, Francesco Cottone, Fabio Efficace, Marie Préau, Célia Touraine, Gandhi Laurent Damaj, Stéphanie Guidez, Gaëlle Labouré, Pauline Lionne‐Huyghe, Antoine Bonnet, Cécile Leyronnas, Romain Guièze, Vincent Launay, Bernard Drénou, Olivier Fitoussi, Laurence Detourmignies, Carole Soussain, Florence Lachenal, Gian Matteo Pica, Adeline Bernier, Émilie Charton, Hervé Ghesquières

0Citations signalées, ce qui n’est pas une note de qualité

21Institutions déclarées

2Pays d’affiliation déclarés

Rattachement africain : fr, it. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Introduction: Few quality of life (QoL) data are available for diffuse large B-cell lymphoma (DLBCL) patients during the first year of diagnosis. Due to the disease and treatment, patients can adapt to their condition and then change their criteria to assess QoL over time, resulting in a response shift (RS) effect. This study aims to provide QoL level for DLBCL patients at diagnosis and after 1 year, and to assess the occurrence of a RS effect. Methods: Data from DLBCL patients prospectively included in the French multicentric cohort REALYSA were used. QoL was collected at diagnosis and at 1 year using the EORTC QLQ-C30 and QLQ-NHL-HG29 (non-Hodgkin high-grade lymphoma) questionnaires. The recently validated QLQ-NHL-HG29 specific questionnaire assesses 5 symptomatic dimensions: symptom burden (SB), neuropathy (NP), physical condition/fatigue (PC), emotional impact (EI), worries/fears about health and functioning (WF). A score is generated per dimension on a 0 to 100 scale. Analyses were done on patients who received standard first-line immunochemotherapy regimen, with QoL questionnaire at diagnosis and at 1 year, and without relapse before 1 year questionnaire completion to avoid bias related to second line therapy. Scores were reported according to age, gender, performance status (PS) and disease stage. We examined the prevalence of clinically important problems/symptoms on QLQ-C30 scales at patient level using validated thresholds (Giesinger et al. J Clin Epidemiol. 2020). The potential occurrence of a RS effect was explored using the Oort procedure. Results: Between Nov 2018 and Dec 2021, 3116 patients were enrolled in REALYSA including 1198 DLBCL. Among 964 patients without relapse at 1 year, 523 had completed questionnaires at baseline and 1 year. For Global QoL, 57% of patients presented clinically important problems at baseline and 42% at 1 year. Regarding the QLQ-NHL-HG29, the mean PC score was 32 (SD 25) [PS 0–1 vs. 2: 29 (SD 24) vs. 47 (SD 25)] at baseline and 23 (SD 21) [PS 0–1 vs. 2: 22 (SD 20) vs. 27 (SD 22)] at 1 year; the mean NP score was 12 (SD 20) [PS 0–1 vs. 2: 11 (SD 19) vs. 16 (SD 26)] at baseline and 23 (SD 28) [PS 0–1 vs. 2: 23 (SD 27) vs. 24 (SD 29)] at 1 year. Among the QLQ-NHL-HG29, a RS effect was observed for NP, PC and WF. The highest effect was observed for NP (Figure 1), suggesting that there is no increase in NP level at 1 year compared to baseline (mean change of -1 points (SD 1)). If no RS effect was considered, it would have been concluded that the NP level had increased at 1 year compared to diagnosis (mean change of 12 points (SD 11)). The research was funded by: Institut National du Cancer (INCa, N°2021-130) Keyword: Aggressive B-cell non-Hodgkin lymphoma No conflicts of interests pertinent to the abstract.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Quality of life and response shift effect of diffuse large B‐cell lymphoma French patients included in prospective real‐life REALYSA cohort in the first year after diagnosis
Date Crossref: 01/06/2023
Éditeur: Wiley
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

Centre Léon Bérard pays non établi dans la notice
Organisation à but non lucratif
The Lymphoma Academic Research Organisation pays non établi dans la notice
Institution
Inserm pays non établi dans la notice
Organisme public
Université de Montpellier pays non établi dans la notice
Université ou école supérieure
Centre Hospitalier Universitaire de Montpellier pays non établi dans la notice
Établissement de santé
Institute for Neurosciences of Montpellier pays non établi dans la notice
Structure de recherche
Fondazione Gimema Onlus pays non établi dans la notice
Organisation à but non lucratif
Lyon 1 Université pays non établi dans la notice
Université ou école supérieure
Institut de Recherche en Cancérologie de Montpellier pays non établi dans la notice
Structure de recherche
Centre Hospitalier Universitaire de Poitiers pays non établi dans la notice
Établissement de santé
Centre Hospitalier d'Arras pays non établi dans la notice
Établissement de santé
Centre hospitalier Bretagne Atlantique pays non établi dans la notice
Établissement de santé

Centre Léon Bérard, The Lymphoma Academic Research Organisation et Inserm, avec 9 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Lymphoma Diagnosis and Treatment

Consulter la publication primaire Ouvrir le DOI